Nitric oxide in the pathogenesis of cardiac disease.

Leopoldo Raij

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Endothelial dysfunction is characterized by a vasoconstrictive and prothrombotic state in the vasculature; it plays a role in all stages of cardiac disease and is a significant independent predictor of cardiovascular outcomes. Nitric oxide (NO) performs multiple biologic activities in the endothelium, including vasodilation and antithrombotic actions. Reduced NO bioactivity is a major component of endothelial dysfunction. Impaired NO bioactivity is an important factor in the pathogenesis of atherosclerosis and in the metabolic syndrome. The functions of NO bioactivity in the heart go well beyond those in the endothelium, as all 3 NO synthase (NOS) isoforms-endothelial NOS, neuronal NOS, and inducible NOS-are expressed in cardiac myocytes and mediate systolic, diastolic, and chronotropic cardiac functions. Impairment of NO bioactivity is a pathogenic factor in various forms of cardiac disease. Although these findings support the potential use of NO-targeted therapies for treatment of cardiac disease, the complexities of the biologic actions of NO in the vasculature and heart are such that development of therapies is still largely in the preliminary stages.

Original languageEnglish
Pages (from-to)30-39
Number of pages10
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume8
Issue number12 Suppl 4
StatePublished - Dec 1 2006

Fingerprint

Heart Diseases
Nitric Oxide
Nitric Oxide Synthase
Endothelium
Nitric Oxide Synthase Type III
Cardiac Myocytes
Vasodilation
Atherosclerosis
Protein Isoforms
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Nitric oxide in the pathogenesis of cardiac disease. / Raij, Leopoldo.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 8, No. 12 Suppl 4, 01.12.2006, p. 30-39.

Research output: Contribution to journalArticle

@article{23d3da9a5b2941eba6cbfbca13a9ee32,
title = "Nitric oxide in the pathogenesis of cardiac disease.",
abstract = "Endothelial dysfunction is characterized by a vasoconstrictive and prothrombotic state in the vasculature; it plays a role in all stages of cardiac disease and is a significant independent predictor of cardiovascular outcomes. Nitric oxide (NO) performs multiple biologic activities in the endothelium, including vasodilation and antithrombotic actions. Reduced NO bioactivity is a major component of endothelial dysfunction. Impaired NO bioactivity is an important factor in the pathogenesis of atherosclerosis and in the metabolic syndrome. The functions of NO bioactivity in the heart go well beyond those in the endothelium, as all 3 NO synthase (NOS) isoforms-endothelial NOS, neuronal NOS, and inducible NOS-are expressed in cardiac myocytes and mediate systolic, diastolic, and chronotropic cardiac functions. Impairment of NO bioactivity is a pathogenic factor in various forms of cardiac disease. Although these findings support the potential use of NO-targeted therapies for treatment of cardiac disease, the complexities of the biologic actions of NO in the vasculature and heart are such that development of therapies is still largely in the preliminary stages.",
author = "Leopoldo Raij",
year = "2006",
month = "12",
day = "1",
language = "English",
volume = "8",
pages = "30--39",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "12 Suppl 4",

}

TY - JOUR

T1 - Nitric oxide in the pathogenesis of cardiac disease.

AU - Raij, Leopoldo

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Endothelial dysfunction is characterized by a vasoconstrictive and prothrombotic state in the vasculature; it plays a role in all stages of cardiac disease and is a significant independent predictor of cardiovascular outcomes. Nitric oxide (NO) performs multiple biologic activities in the endothelium, including vasodilation and antithrombotic actions. Reduced NO bioactivity is a major component of endothelial dysfunction. Impaired NO bioactivity is an important factor in the pathogenesis of atherosclerosis and in the metabolic syndrome. The functions of NO bioactivity in the heart go well beyond those in the endothelium, as all 3 NO synthase (NOS) isoforms-endothelial NOS, neuronal NOS, and inducible NOS-are expressed in cardiac myocytes and mediate systolic, diastolic, and chronotropic cardiac functions. Impairment of NO bioactivity is a pathogenic factor in various forms of cardiac disease. Although these findings support the potential use of NO-targeted therapies for treatment of cardiac disease, the complexities of the biologic actions of NO in the vasculature and heart are such that development of therapies is still largely in the preliminary stages.

AB - Endothelial dysfunction is characterized by a vasoconstrictive and prothrombotic state in the vasculature; it plays a role in all stages of cardiac disease and is a significant independent predictor of cardiovascular outcomes. Nitric oxide (NO) performs multiple biologic activities in the endothelium, including vasodilation and antithrombotic actions. Reduced NO bioactivity is a major component of endothelial dysfunction. Impaired NO bioactivity is an important factor in the pathogenesis of atherosclerosis and in the metabolic syndrome. The functions of NO bioactivity in the heart go well beyond those in the endothelium, as all 3 NO synthase (NOS) isoforms-endothelial NOS, neuronal NOS, and inducible NOS-are expressed in cardiac myocytes and mediate systolic, diastolic, and chronotropic cardiac functions. Impairment of NO bioactivity is a pathogenic factor in various forms of cardiac disease. Although these findings support the potential use of NO-targeted therapies for treatment of cardiac disease, the complexities of the biologic actions of NO in the vasculature and heart are such that development of therapies is still largely in the preliminary stages.

UR - http://www.scopus.com/inward/record.url?scp=34250748949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250748949&partnerID=8YFLogxK

M3 - Article

C2 - 17170604

AN - SCOPUS:34250748949

VL - 8

SP - 30

EP - 39

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 12 Suppl 4

ER -